uniQure is a gene therapy company developing treatments based on adeno-associated virus (AAV) vectors for severe genetic diseases. It commercialized HEMGENIX (etranacogene dezaparvovec), a one-time gene therapy for hemophilia B, and advances a pipeline that has included programs in Huntington’s disease and other rare disorders. The platform centers on AAV manufacturing and delivery know-how aimed at durable expression of therapeutic genes after a single administration.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 5.3 | — | -37.7 | — |
| Q3 2025 | 3.7 | — | -80.5 | — |
| Q4 2025 | 5.6 | — | -37.1 | — |
| Q1 2026 | 3.6 | — | -53.5 | — |
| Q2 2026 | 5.8 | 11% | -81.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Ocular Therapeutix, Inc. (OCUL), Structure Therapeutics Inc. (GPCR), Innoviva, Inc. (INVA), Dorchester Minerals, L.P. (DMLP), Azenta, Inc. (AZTA), COMPASS Pathways plc (CMPS)